News Releases

Sep 11, 2020
Sangamo Therapeutics Appoints Kenneth Hillan to Its Board of Directors
- Stephen Dilly to resign from the Sangamo board effective September 30, 2020 BRISBANE, Calif. --(BUSINESS WIRE)--Sep. 11, 2020-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, today announced the appointment of Dr. Kenneth Hillan , an accomplished biotechnology executive,
Additional Formats
PDF Version
Jun 24, 2020
Sangamo Announces R&D Organization Changes
BRISBANE, Calif. --(BUSINESS WIRE)--Jun. 24, 2020-- Sangamo Therapeutics, Inc. (Nasdaq: SGMO) today announced changes to its research and development organization. Going forward, research and development will each be managed as separate functions. A search for a Head of Development is underway.
Additional Formats
PDF Version
Jun 18, 2020
Pfizer and Sangamo Announce Updated Phase 1/2 Results Showing Sustained Factor VIII Activity Levels and No Bleeding Events or Factor Usage in 3e13 vg/kg Cohort Following giroctocogene fitelparvovec (SB-525) Gene Therapy
— Dosing of the first patient in the pivotal Phase 3 study anticipated in second half of 2020 — NEW YORK & BRISBANE, Calif. --(BUSINESS WIRE)--Jun. 18, 2020-- Pfizer Inc. (NYSE:PFE)   and   Sangamo Therapeutics, Inc. (Nasdaq:SGMO), a genomic medicines company, today announced updated follow-up data
Additional Formats
PDF Version
Displaying 1 - 10 of 24